High-intensity Interval Training Training Protocols on Cardiorespiratory Parameters in Patients With Type 2 Diabetes

April 7, 2020 updated by: Cemile Bozdemir Ozel, Hacettepe University

The Effects of Different High-intensity Interval Training Training Protocols on Cardiorespiratory Parameters in Patients With Type 2 Diabetes

Aim: To assess whether there are different training effects on glucose concentration and cardiorespiratory parameters of different high-intensity training protocols in patients with type 2 diabetes.

Type 2 diabetes is a highly prevalent disease associated with cardiovascular disease leading to high levels of mortality, morbidity and health expenditure, characterized by impaired glucose control during activities and reduced aerobic exercise capacity .

Exercise training is the most effective way to improve compliance, reduce blood glucose concentration and increase insulin sensitivity. Training increases muscle capacity, oxidative capacity and glucose transport, peripheral insulin sensitivity is improved.

Exercise training with high-intensity interval (resting and exercise period) High Intensity Interval Training (HIIT) is a form of exercise training that has recently been widely used in the management of type 2 diabetes, including short duration high intensity exercise periods and lower severity or passive rest periods. There are different HIIT exercise training programs according to physiological responses in the literature. However, long-term and short-term HIIT training training programs were not compared in terms of their effect on glucose concentration and cardiorespiratory fitness. The aim of this study was to compare the effects of different HIIT exercise training programs so that exercise programs for patients with type 2 diabetes could be planned more effectively.

Study Overview

Status

Completed

Conditions

Detailed Description

This study will be participated patients with Type 2 diabetes. Patients' laboratory values, pulmonary function test, respiratory muscle strength, exercise capacity, physical activity level, quality of life will be evaluated.

Pulmonary function test will be assesed with spirometer, respiratory muscle strength will be evaluated with mouth pressure. Exercise capacity will be evaluated using six minute walking test, incremental shuttle walk test, cycle ergometer. Muscle oxigeneration will be asssed with wearable lactate threshold predicting device. Physical activity level will be evaluated trial accelerometer.

Then, patients will be randomly divided two high intensity interval exercise training groups.

First group: short duration high intensity exercise training (Exercise load phase : 30sn %100 Patients performance, rest phase: 120sn %25 patients performance) Second group: Long duration high intensity interval exercise training (Exercise load phase : 4 dk %100 Patients performance, rest phase: 120sn %25 patients performance) All patients will participate three times a week during eight weeks. The muscle oxigeneration, blood glucose consantration, blood pressure, heart rate will be recorded before and after each exercise session. After 8 week, all test will be done again.

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • State
      • Ankara, State, Turkey, 06100
        • Hacettepe University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 64 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • diagnosis of type 2 diabetes
  • aged 18-64 years
  • patients can walk and cooperative
  • body mass index is less than 40 kg / m2

Exclusion Criteria:

Individuals have known lung disease,have undergone any cardiac event or surgery within the past six months, have uncontrolled hypertension, and have diabetic complications such as nephropathy, retinopathy and severe neuropathy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: short duration group
30sn %100 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
exercise Short duration high intensity training
Other Names:
  • training
EXPERIMENTAL: long duration group
4dk %85 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
exercise Long duration high intensity training
Other Names:
  • training

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
muscle oxigeneration
Time Frame: Change from baseline muscle oxigeneration at 8 weeks
It is evaluate with wearable lactate threshold device on gastrocinemius
Change from baseline muscle oxigeneration at 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The blood glucose consentration
Time Frame: before and after 8 weeks
It is evaluate with sample from blood
before and after 8 weeks
Functional Exercise capacity
Time Frame: before and after 8 weeks
İt is evaluated with six minute walk test
before and after 8 weeks
Maximal exercise capacity
Time Frame: before and after 8 weeks
İt is evaluated using with incremental shuttle test
before and after 8 weeks
Symptom limited maximal exercise capacity
Time Frame: before and after 8 weeks
İt is evaluated with cycle ergometer test
before and after 8 weeks
Lipit profile-High density lipoprotein cholesterol
Time Frame: before and after 8 weeks
High density lipoprotein cholesterol wiil be assesed
before and after 8 weeks
Lipit profile- low density lipoprotein cholesterol
Time Frame: before and after 8 weeks
low density lipoprotein cholesterol wiil be assesed
before and after 8 weeks
Lipit profile- trigliseride
Time Frame: before and after 8 weeks
trigliseride wiil be assesed
before and after 8 weeks
pulmonary parameter-Forced vital capacity
Time Frame: before and after 8 weeks
Forced vital capacity will be evaluated
before and after 8 weeks
pulmonary parameter-Forced vital capacity in the first second
Time Frame: before and after 8 weeks
Forced vital capacity in the first second will be evaluated
before and after 8 weeks
pulmonary parameter-Mid expiratory flow rate
Time Frame: before and after 8 weeks
Mid expiratory flow rate will be evaluated
before and after 8 weeks
pulmonary parameter-Peak expiratory flow
Time Frame: before and after 8 weeks
Peak expiratory flow will be evaluated
before and after 8 weeks
Respiratory muscle strength
Time Frame: before and after 8 weeks
It is evaluated with mouth pressure
before and after 8 weeks
Physical activity level
Time Frame: before and after 8 weeks
ıt is assessed using accelerometer
before and after 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Cemile Bozdemir Özel, McS, Hacettepe University Physiotherapy and Rehabilitation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 2, 2018

Primary Completion (ACTUAL)

September 20, 2018

Study Completion (ACTUAL)

January 17, 2020

Study Registration Dates

First Submitted

February 6, 2018

First Submitted That Met QC Criteria

April 2, 2018

First Posted (ACTUAL)

April 3, 2018

Study Record Updates

Last Update Posted (ACTUAL)

April 9, 2020

Last Update Submitted That Met QC Criteria

April 7, 2020

Last Verified

April 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe